Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12115089 | 0.94 | CDK8 (0.41) | CDK8HRH3LIPGCTPS1POLB | |
| SCHEMBL1320572 | 0.94 | CDK8 (0.45) | CDK8HRH3CTPS1POLBMAPT | |
| SCHEMBL1318385 | 0.89 | CDK8 (0.42) | CDK8HRH3LIPGCTPS1POLB | |
| SCHEMBL12115149 | 0.85 | CDK8 (0.41) | CDK8HRH3CTPS1POLBMAPT | |
| SCHEMBL12115071 | 0.85 | CDK8 (0.47) | CDK8HRH3CTPS1POLBMAPT | |
| SCHEMBL1317780 | 0.84 | MEN1 (0.39) | CDK8HRH3SCN9AHTR1BOPRK1 | |
| SCHEMBL12115132 | 0.84 | CDK8 (0.41) | CDK8HRH3CTPS1POLBMAPT | |
| SCHEMBL12115091 | 0.84 | CDK8 (0.41) | CDK8HRH3LIPGCTPS1POLB | |
| SCHEMBL12115108 | 0.84 | CDK8 (0.43) | CDK8HRH3CTPS1POLBMAPT | |
| SCHEMBL12205590 | 0.84 | CDK8 (0.41) | CDK8HRH3CTPS1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380878-B1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2380878-B1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| EP-2380878-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380878-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010082563-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | BMP2, BMP4, BMP1 | CDK8 1711/4885HRH3 2680/4885LIPG 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.